iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Biocon's cancer drug gets USFDA nod, but investors remain cautious

7 Feb 2024 , 11:16 AM

On February 7, early trading saw a 1% decrease in the price of Biocon’s shares. The United States Food and Drug Administration (USFDA) has tentatively approved the company’s abbreviated new drug application (ANDA) for dasatinib tablets.

Biocon was trading on the BSE at ₹295.15 at 9:29 a.m., down ₹3.60, or 1.21%.

This medication is approved for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia. Adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who have not responded well to previous treatments can also be treated with it.

To record the unaudited standalone and consolidated financial statements for the quarter and nine months ended December 31, 2023, the company’s board will convene on February 8.

On February 6, 2024, the share reached a 52-week high of ₹307, and on March 21, 2023, it reached a 52-week low of ₹191.60. It is currently trading 54.04% above its 52-week low and 3.86% below its 52-week high.

For feedback and suggestions, write to us at editorial@iifl.com

Branding Asia

Related Tags

  • Biocon
  • USFDA
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.